Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1991 5
1992 7
1993 15
1994 2
1995 2
1996 5
1997 6
1998 6
1999 16
2000 7
2001 14
2002 8
2003 12
2004 3
2005 4
2006 12
2007 7
2008 11
2009 7
2010 2
2011 2
2012 2
2013 4
2014 9
2015 8
2016 6
2017 5
2018 5
2019 9
2020 3
2021 3
2022 3
2023 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

208 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.
Kaye KS, Belley A, Barth P, Lahlou O, Knechtle P, Motta P, Velicitat P. Kaye KS, et al. JAMA. 2022 Oct 4;328(13):1304-1314. doi: 10.1001/jama.2022.17034. JAMA. 2022. PMID: 36194218 Free PMC article. Clinical Trial.
IMPORTANCE: Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor combination and a potential empirical therapy for resistant gram-negative infections. ...A total of 1.7% (9/516) of participants who received cefepime/enmetazobactam and 0.8% (4/518) …
IMPORTANCE: Cefepime/enmetazobactam is a novel beta-lactam/beta-lactamase inhibitor combination and a potential empirical therapy for …
Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
Wagenlehner FM, Gasink LB, McGovern PC, Moeck G, McLeroth P, Dorr M, Dane A, Henkel T; CERTAIN-1 Study Team. Wagenlehner FM, et al. N Engl J Med. 2024 Feb 15;390(7):611-622. doi: 10.1056/NEJMoa2304748. N Engl J Med. 2024. PMID: 38354140 Clinical Trial.
Composite success occurred in 207 of 293 patients (70.6%) in the cefepime-taniborbactam group and in 83 of 143 patients (58.0%) in the meropenem group. Cefepime-taniborbactam was superior to meropenem regarding the primary outcome (treatment difference, 12.6 percent …
Composite success occurred in 207 of 293 patients (70.6%) in the cefepime-taniborbactam group and in 83 of 143 patients (58.0%) in th …
Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.
Aguilar-Guisado M, Espigado I, Martín-Peña A, Gudiol C, Royo-Cebrecos C, Falantes J, Vázquez-López L, Montero MI, Rosso-Fernández C, de la Luz Martino M, Parody R, González-Campos J, Garzón-López S, Calderón-Cabrera C, Barba P, Rodríguez N, Rovira M, Montero-Mateos E, Carratalá J, Pérez-Simón JA, Cisneros JM. Aguilar-Guisado M, et al. Lancet Haematol. 2017 Dec;4(12):e573-e583. doi: 10.1016/S2352-3026(17)30211-9. Epub 2017 Nov 15. Lancet Haematol. 2017. PMID: 29153975 Clinical Trial.
EAT based on an antipseudomonal beta-lactam drug as monotherapy (ceftazidime or cefepime, meropenem or imipenem, or piperacillin-tazobactam) or as combination therapy (with an aminoglycoside, fluoroquinolone, or glycopeptide) was started according to local protocols and fo …
EAT based on an antipseudomonal beta-lactam drug as monotherapy (ceftazidime or cefepime, meropenem or imipenem, or piperacillin-tazo …
Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Seo YB, Lee J, Kim YK, Lee SS, Lee JA, Kim HY, Uh Y, Kim HS, Song W. Seo YB, et al. BMC Infect Dis. 2017 Jun 7;17(1):404. doi: 10.1186/s12879-017-2502-x. BMC Infect Dis. 2017. PMID: 28592240 Free PMC article. Clinical Trial.
After the recruitment of six participants, assignment to the cefepime treatment group was stopped because of an unexpectedly high treatment failure rate. ...The clinical and microbiological response to PTZ treatment was estimated to be 94% and was similar to the response t …
After the recruitment of six participants, assignment to the cefepime treatment group was stopped because of an unexpectedly high tre …
A Randomized Clinical Trial of Bayesian-Guided Beta-Lactam Infusion Strategy and Associated Bacterial Resistance and Clinical Outcomes in Patients With Severe Pneumonia.
Maranchick NF, Trillo-Alvarez C, Kariyawasam V, Venugopalan V, Kwara A, Rand K, Peloquin CA, Alshaer MH. Maranchick NF, et al. Ther Drug Monit. 2024 Feb 1;46(1):95-101. doi: 10.1097/FTD.0000000000001144. Epub 2023 Nov 15. Ther Drug Monit. 2024. PMID: 38018847 Free PMC article. Clinical Trial.
METHODS: Adult intensive care patients receiving cefepime, meropenem, or piperacillin-tazobactam for severe pneumonia caused by Gram-negative bacteria were randomized to receive beta-lactams as an intermittent (30 minutes) or continuous (24 hours) infusion. ...Thirty-five …
METHODS: Adult intensive care patients receiving cefepime, meropenem, or piperacillin-tazobactam for severe pneumonia caused by Gram- …
Single-Center Investigation of the Pharmacokinetics of WCK 4282 (Cefepime-Tazobactam Combination) in Renal Impairment.
Preston RA, Mamikonyan G, Mastim M, Garg D, Kemper CJ, Xu A, Yeole R, Chavan R, Friedland HD, Bhatia A. Preston RA, et al. Antimicrob Agents Chemother. 2019 Sep 23;63(10):e00873-19. doi: 10.1128/AAC.00873-19. Print 2019 Oct. Antimicrob Agents Chemother. 2019. PMID: 31332068 Free PMC article. Clinical Trial.
WCK 4282 is a combination product of cefepime (FEP) and tazobactam (TAZ) in a 1:1 ratio currently under development for the treatment of multidrug-resistant Gram-negative bacterial infections. ...
WCK 4282 is a combination product of cefepime (FEP) and tazobactam (TAZ) in a 1:1 ratio currently under development for the treatment …
Clinical efficacy and safety of cefepime in febrile neutropenic patients with lung cancer.
Fujita M, Ouchi H, Inoue Y, Inoshima I, Ohshima T, Yoshimura C, Wataya H, Kawasaki M, Tokunaga S, Nakanishi Y; Lung Oncology Group in Kyushu (LOGIK). Fujita M, et al. J Infect Chemother. 2010 Apr;16(2):113-7. doi: 10.1007/s10156-010-0030-3. Epub 2010 Feb 4. J Infect Chemother. 2010. PMID: 20130951 Clinical Trial.
A multi-institution prospective study of cefepime for the treatment of FN in lung cancer patients was conducted. The objective of this study was to determine the efficacy and safety of cefepime for FN in lung cancer patients. Cefepime (2 g x 2/day) was admini …
A multi-institution prospective study of cefepime for the treatment of FN in lung cancer patients was conducted. The objective of thi …
A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia.
Edelstein H, Chirurgi V, Oster S, Karp R, Cassano K, Aiken S, McCabe R. Edelstein H, et al. J Antimicrob Chemother. 1991 Oct;28(4):569-75. doi: 10.1093/jac/28.4.569. J Antimicrob Chemother. 1991. PMID: 1761451 Clinical Trial.
To study the efficacy and safety of cefepime for treatment of pneumonia, 65 patients were randomized to therapy with either cefepime or ceftazidime at a two to one ratio. ...Bacteriological cure was achieved in 31 (91%) of cefepime patients and 17 (100%) ceft …
To study the efficacy and safety of cefepime for treatment of pneumonia, 65 patients were randomized to therapy with either cefepi …
Randomized Noninferiority Trial of Cefoperazone-Sulbactam versus Cefepime in the Treatment of Hospital-Acquired and Healthcare-Associated Pneumonia.
Liu JW, Chen YH, Lee WS, Lin JC, Huang CT, Lin HH, Liu YC, Chuang YC, Tang HJ, Chen YS, Ko WC, Lu MC, Wang FD. Liu JW, et al. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00023-19. doi: 10.1128/AAC.00023-19. Print 2019 Aug. Antimicrob Agents Chemother. 2019. PMID: 31138577 Free PMC article. Clinical Trial.
Participants were randomly assigned to the cefoperazone-sulbactam (2 g of each per 12 h) or cefepime (2 g per 12 h) arm. Clinical and microbiological responses were evaluated at early posttherapy and test-of-cure visits. ...Cefoperazone-sulbactam at 2 g every 12 h was noni …
Participants were randomly assigned to the cefoperazone-sulbactam (2 g of each per 12 h) or cefepime (2 g per 12 h) arm. Clinical and …
208 results